Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

view original post

Investors today are cheering envudeucitinib’s Phase 3 edge in oral TYK2 psoriasis as well as Alumis’ plans to raise fresh capital.